{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-22-022313","form_type":"8-K","ticker":"BEAM","cik":"0001745999","company_name":"Beam Therapeutics Inc.","filed_at":"2022-11-07T23:59:59+00:00","discovered_at":"2026-05-14T18:03:51.961599+00:00","generated_at":"2026-06-22T05:38:33.699634+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Beam Therapeutics Q3 net loss $109.6M; BEACON trial enrollment started for BEAM-101","bullets":["Net loss $109.6M ($1.56/sh) vs $28.1M ($0.42/sh) in Q3 2021; R&D spend $85.3M.","Cash, cash equivalents and marketable securities $1.1B as of Sep 30, 2022, up from $965.6M.","Patient recruitment underway in BEACON trial for BEAM-101; first sickle cell patient enrollment expected by year-end 2022.","BEAM-302 nominated as development candidate for alpha-1 antitrypsin deficiency; targeting in vivo DNA correction of E342K mutation.","BEAM-201 IND response submitted to FDA after clinical hold; no BEAM-102 IND filing in 2022."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-22-022313","json":"https://secwatch.observer/filing/0000950170-22-022313.json","markdown":"https://secwatch.observer/filing/0000950170-22-022313.md","text":"https://secwatch.observer/filing/0000950170-22-022313.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1745999/000095017022022313/0000950170-22-022313-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1745999/000095017022022313/beam-20221107.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-22T05:38:33.699634+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"1b52f7efefcea9e1e9d829a8e5e7b0a3415b8a73","claim":"Beam Therapeutics Inc. reported financial results for the quarter ended September 30, 2022.","evidence_excerpt":"On November 7, 2022, Beam Therapeutics Inc. (the “Company”) issued a press release announcing the Company’s financial results for the quarter ended September 30, 2022.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1745999/000095017022022313/0000950170-22-022313-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the quarter ended September 30, 2022"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}